UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Breast cancer therapy in China: Introducing the Special Collection

Cancer, 2024-04, Vol.130 (S8), p.1368-1370

2024

Volltextzugriff (PDF)

Adjuvant cyclin‐dependent kinase 4/6 inhibition in hormone receptor–positive breast cancer: One Monarch to rule them all?

Cancer, 2021-09, Vol.127 (18), p.3302-3309

2021

Volltextzugriff (PDF)

Targeting forkhead box M1 transcription factor in breast cancer

Biochemical pharmacology, 2018-08, Vol.154, p.407-413

2018

Volltextzugriff (PDF)

Therapy after cyclin‐dependent kinase inhibition in metastatic hormone receptor‐positive breast cancer: Resistance mechanisms and novel treatment strategies

Cancer, 2020-08, Vol.126 (15), p.3400-3416

2020

Volltextzugriff (PDF)

Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers

Breast cancer research and treatment, 2012-08, Vol.135 (1), p.39-48

2012

Volltextzugriff (PDF)

When the personal becomes political: The impact of the Dobbs decision on women with cancer

Cancer, 2023-01, Vol.129 (2), p.171-174

2023

Volltextzugriff (PDF)

Progress in breast cancer research amid the COVID‐19 gloom

Cancer, 2020-08, Vol.126 (S16), p.3809-3810

2020

Volltextzugriff (PDF)

Social media and clinical trials: The pros and cons gain context when the patient is at the center

Cancer, 2018-12, Vol.124 (24), p.4618-4621

2018

Volltextzugriff (PDF)

Lymph node involvement: Positive about the role of the recurrence score in estrogen‐driven breast cancer?

Cancer, 2019-01, Vol.125 (2), p.177-180

2019

Volltextzugriff (PDF)

Molecular homology and difference between spontaneous canine mammary cancer and human breast cancer

Cancer research (Chicago, Ill.), 2014-09, Vol.74 (18), p.5045-5056

2014

Volltextzugriff (PDF)

Emerging use of nanoparticles in diagnosis and treatment of breast cancer

The lancet oncology, 2006-08, Vol.7 (8), p.657-667

2006

Volltextzugriff (PDF)

Paclitaxel Induces Micronucleation and Activates Pro-Inflammatory cGAS-STING Signaling in Triple-Negative Breast Cancer

Molecular cancer therapeutics, 2021-12, Vol.20 (12), p.2553-2567

2021

Volltextzugriff (PDF)

Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor

Cancer research (Chicago, Ill.), 2008-12, Vol.68 (23), p.9712-9722

2008

Volltextzugriff (PDF)

Creating the High School Pipeline for Future Deaf Scientists in Academic Medicine

Academic medicine, 2023-11, Vol.98 (11), p.1235-1235

2023

Volltextzugriff (PDF)

The WNT10B Network Is Associated with Survival and Metastases in Chemoresistant Triple-Negative Breast Cancer

Cancer research (Chicago, Ill.), 2019-03, Vol.79 (5), p.982-993

2019

Volltextzugriff (PDF)

Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells

Cancer research (Chicago, Ill.), 2008-04, Vol.68 (7), p.2479-2488

2008

Volltextzugriff (PDF)

Systemic therapy for early‐stage HER2‐positive breast cancers: Time for a less‐is‐more approach?

Cancer, 2015-02, Vol.121 (4), p.517-526

2015

Volltextzugriff (PDF)

Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells

Molecular cancer therapeutics, 2011-08, Vol.10 (8), p.1460-1469

2011

Volltextzugriff (PDF)

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy

Breast cancer research and treatment, 2013-10, Vol.141 (3), p.437-446

2013

Volltextzugriff (PDF)

Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance

Anti-cancer agents in medicinal chemistry, 2012-02, Vol.12 (2), p.151-162

2012

Volltextzugriff (PDF)

Improving Outcomes for High-Risk Hormone Receptor-Positive Breast Cancer With CDK Inhibition

Journal of clinical oncology, 2022-04, Vol.40 (11), p.1142-1146

2022

Volltextzugriff (PDF)

A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782)

Cancer medicine (Malden, MA), 2022-11, Vol.11 (21), p.3969-3981

2022

Volltextzugriff (PDF)

Proteomic Identification of Glycosylphosphatidylinositol Anchor-dependent Membrane Proteins Elevated in Breast Carcinoma

The Journal of biological chemistry, 2012-07, Vol.287 (30), p.25230-25240

2012

Volltextzugriff (PDF)

Using a Neoadjuvant Approach for Evaluating Novel Therapies for Patients With Breast Cancer

American Society of Clinical Oncology educational book, 2018-05, Vol.38 (38), p.47-55

2018

Volltextzugriff (PDF)

1 – 25 von 147

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(139)
Mit Volltextzugriff
(120)

Publikationsform

Sprache

Englisch
(147)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Breast cancer therapy in China: Introducing the Special Collection

Adjuvant cyclin‐dependent kinase 4/6 inhibition in hormone receptor–positive breast cancer: One Monarch to rule them all?

Targeting forkhead box M1 transcription factor in breast cancer

Therapy after cyclin‐dependent kinase inhibition in metastatic hormone receptor‐positive breast cancer: Resistance mechanisms and novel treatment strategies

Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers

When the personal becomes political: The impact of the Dobbs decision on women with cancer

Progress in breast cancer research amid the COVID‐19 gloom

Social media and clinical trials: The pros and cons gain context when the patient is at the center

Lymph node involvement: Positive about the role of the recurrence score in estrogen‐driven breast cancer?

Molecular homology and difference between spontaneous canine mammary cancer and human breast cancer

Emerging use of nanoparticles in diagnosis and treatment of breast cancer

Paclitaxel Induces Micronucleation and Activates Pro-Inflammatory cGAS-STING Signaling in Triple-Negative Breast Cancer

Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor

Creating the High School Pipeline for Future Deaf Scientists in Academic Medicine

The WNT10B Network Is Associated with Survival and Metastases in Chemoresistant Triple-Negative Breast Cancer

Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells

Systemic therapy for early‐stage HER2‐positive breast cancers: Time for a less‐is‐more approach?

Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy

Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance

Improving Outcomes for High-Risk Hormone Receptor-Positive Breast Cancer With CDK Inhibition

Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer

A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782)

Proteomic Identification of Glycosylphosphatidylinositol Anchor-dependent Membrane Proteins Elevated in Breast Carcinoma

Using a Neoadjuvant Approach for Evaluating Novel Therapies for Patients With Breast Cancer

Suchergebnisse filtern